An example of the latter is the FDA-approved commercial CellSearch® kit for the enumeration of CTCs in patients with mCRC, which is based on the use of a mAb against the epithelial cell adhesion molecule (EpCAM), a surface protein expressed by most carcinoma epithelial cells. This evidence concerns the gene EPCAM and carcinoma.